Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
Key Financial Performance
Earnings Per Share (EPS) $-0.42, an improvement from expectations of $-0.49.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI Platform Expansion: Expanded capabilities of proprietary radar AI platform to over 200 billion oncology focused data points.
Clinical Pipeline Progress: Phase 1a trial for LP-184 has progressed well with enrollment now through cohort 12.
AI-Driven Drug Development: Lantern Pharma is focusing on AI and machine learning to transform drug development processes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: Lantern Pharma cautions that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated.
Clinical trial results: Results of clinical trials could significantly impact the company's performance and projections.
Competition: The impact of competition in the pharmaceutical industry may affect Lantern Pharma's market position and financial outcomes.
Regulatory issues: Potential regulatory challenges could arise, affecting the approval and commercialization of their drug candidates.
Market conditions: Economic factors and market conditions may influence the company's operational success and financial stability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
AI and Machine Learning Integration: Lantern Pharma is leveraging AI and machine learning to enhance drug discovery and development processes, aiming to transform precision oncology therapies.
Clinical Pipeline Progress: The company is advancing multiple clinical programs, particularly the Phase 1a trial for LP-184, which has progressed well with enrollment through cohort 12.
Radar AI Platform Expansion: The capabilities of the proprietary radar AI platform have expanded to over 200 billion oncology-focused data points.
Shareholder Value Initiatives: Lantern is focused on initiatives aimed at maximizing shareholder value.
Future Catalysts: The company anticipates multiple value-creating catalysts in the coming quarters as it continues to advance its clinical pipeline and AI platform.
Earnings Expectations: Lantern Pharma reported an EPS of $-0.42, beating expectations of $-0.49.
Clinical Trial Risks: The company cautions that forward-looking statements are subject to risks and uncertainties, particularly regarding clinical trial results and competition.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Lantern Pharma is focused on initiatives to maximize shareholder value, although specific details on share buyback programs or dividend programs were not disclosed in the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the broader plans to roll out the AI modules, particularly the blood-brain barrier penetration module?
A:We’re going to start with a freemium type approach to get people used to using this method. We have a roadmap that we’ll be discussing, probably toward the end of this quarter or early next quarter on what that roadmap is and also some of the business models underlying bringing radar into kind of an agentic life form module by module.
Q:Is the HARMONIC trial still enrolling more patients in the U.S.?
A:The expansion cohort will be both U.S. and Asian, but the expansion cohort is randomized. So it’s not the Asian cohort. It’s just the Asian patients as part of the expansion cohort.
Q:What is the expected timeline for the LP-184 trial enrollment?
A:We expect the trial to be fully enrolled next month. This is now a 60 to 65 patient trial, and we believe that enrollment will be completed next month.
Q:Will the FDA use AI in its evaluation of scientific literature and data?
A:I want to believe that the FDA will definitely have to use AI in its evaluation of scientific literature, data, and perhaps better come through mechanistic inputs from companies on the evaluation of the safety and direction of their new molecules.
Q:What are the risks associated with the FDA using AI?
A:I think there’ll probably be a period in which they evaluate these methods in parallel to the existing methods, and I don’t think they’re going to roll out anything across the board until they’ve concluded, like, six months to one year of these efforts.
Q:Review of Unclear Management Responses
A:Management's responses lacked clarity on the specific timeline for the rollout of AI modules and the exact nature of the freemium model. Additionally, there was vague language regarding the FDA's use of AI, particularly concerning the risks and the timeline for implementation.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO CFO
CFO Margrave
Form file
Inc expectation
Margrave introduction
Pharma Inc
QA President
Transcript Lantern
achievement result
comment QA
expectation reminder
harbor provision
market today
press release
progress copy
purpose harbor
release market
result comment
statement Form
today result
website press
LTRN Transcript
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Unknown3-30
The earnings call presents a mixed picture. While the company is making progress in product development and AI expansion, it faces significant risks, including funding challenges and competitive pressures. Financial metrics show reduced losses, but the need for additional funding and operational risks dampen enthusiasm. The absence of shareholder return discussions and unclear management responses in the Q&A further contribute to a neutral sentiment.
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript
Unknown5-16
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
LTRN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
